Astria Therapeutics Presents New Phase 1a Data Confirming Potential For STAR-0125 To Prevent Hereditary Angioedema Attacks With Dosing 2 Or 4 Times Per Year At The 2023 American College Of Allergy, Asthma, And Immunology Annual Scientific Meeting
Portfolio Pulse from Benzinga Newsdesk
Astria Therapeutics, Inc. (NASDAQ:ATXS) is presenting new data on STAR-0215, a potential preventative therapy for Hereditary Angioedema (HAE), at the American College of Allergy, Asthma, and Immunology. The data supports the potential for STAR-0215 to be dosed once every three or six months. The company's Phase 1b/2 ALPHA-STAR trial is on track, with initial proof-of-concept data expected in Q1 2024.
November 10, 2023 | 1:03 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Astria Therapeutics is presenting promising data on STAR-0215, a potential preventative therapy for HAE. The ongoing Phase 1b/2 trial is expected to deliver initial proof-of-concept data in Q1 2024.
The news is directly related to Astria Therapeutics and its product STAR-0215. The positive data presented and the progress of the ongoing trial could potentially increase investor confidence and positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100